47,868 results match your criteria Hodgkin Disease

Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Outcomes of Flu-Mel-TBI.

Transplant Cell Ther 2021 May 12. Epub 2021 May 12.

Department of Oncology, Co-Director, Blood & Marrow Stem Cell Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, HW04H0, Detroit, MI 48201. Electronic address:

Background: Fludarabine 30 mg/m/day x 5 and melphalan 140 mg/m x 1 (Flu-Mel140) is a commonly used RIC regimen. We hypothesized that addition of 200cGy total body irradiation (TBI) to Flu-Mel140 may improve antitumor activity and transplant outcomes.

Objectives: Primary objectives was overall survival (OS) at 3-year. Read More

View Article and Full-Text PDF

Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL.

Ann Hematol 2021 May 15. Epub 2021 May 15.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

Despite the clinical value of HMGB1 in non-Hodgkin lymphoma (NHL), the impact of HMGB1 protein expression on survival of patients with mature T-cell and NK-cell lymphoma (T/NK-CL) is unknown. Here, we evaluated correlations of HMGB1 expression in tumor tissues with pathophysiological characteristics of disease and determined the prognostic value of HMGB1 expression in relapsed/refractory T/NK-CL. HMGB1 expression was detected by immunohistochemistry (IHC) in 66 cases of relapsed/refractory T/NK-CL, and specimens were classified as high or low HMGB1 expression. Read More

View Article and Full-Text PDF

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2021 May 11. Epub 2021 May 11.

Department of Oncology and Haematology, Humanitas Clinical and Research Center, IRCCS, Humanitas University, Milan, Italy.

Background: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis. Loncastuximab tesirine is a CD19-directed antibody-drug conjugate with encouraging phase 1 single-agent antitumour activity and acceptable safety in non-Hodgkin lymphoma. We aimed to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL. Read More

View Article and Full-Text PDF

MRI features of breast implant-associated anaplastic large cell lymphoma: a pictorial review.

Br J Radiol 2021 May 14:20210093. Epub 2021 May 14.

Division of Breast Radiology, IEO - European Institute of Oncology IRCCS, Milan, Italy.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare and newly recognized subtype of T cell Non-Hodgkin Lymphoma (NHLs) associated with breast implants.The mechanism involved in the development of this kind of lymphoma is still uncertain.BIA-ALCL is generally an indolent disease localized to the breast implant and its capsule and effectively treated with capsulectomy alone without chemotherapy. Read More

View Article and Full-Text PDF

Pineal gland hypermetabolic involvement without central nervous system symptoms in a pediatric patient with primary nodular sclerosis subtype classical Hodgkin Lymphoma.

Pediatr Hematol Oncol 2021 May 14:1-6. Epub 2021 May 14.

Division of Pediatric Hematology/Oncology, Peyton Manning Children's Hospital at Ascension St. Vincent, Indianapolis, Indiana, USA.

This case report presents the first reported pediatric case of primary classical nodular sclerosing Hodgkin Lymphoma (HL) with pineal gland involvement, presenting without CNS symptoms, which completely resolved after 2 cycles of chemotherapy. The 12 year-old male first presented with a right inguinal mass and external iliac lymphadenopathy accompanied by B symptoms. He was diagnosed with stage IV B classical HL, and as part of the staging work-up, a full-body PET/CT scan was performed. Read More

View Article and Full-Text PDF

Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.

Eur J Haematol 2021 May 13. Epub 2021 May 13.

Department of Internal Medicine, Tampere University Hospital, Box 2000, FI-33521, Tampere, Finland.

Objectives: The aim was to identify the clinical characteristics, outcome and antimicrobial susceptibility of healthcare-associated bloodstream infections (BSIs) in hematological patients.

Methods: This retrospectively collected laboratory-based surveillance data includes 3404 healthcare-associated BSIs in 2296 patients with a hematological malignancy in hospitals participating in the Finnish Hospital Infection Program from January 1, 2006 to December 31, 2016.

Results: The most common underlying diseases were acute myelogenous leukemia (35%) and non-Hodgkin lymphoma (22%). Read More

View Article and Full-Text PDF

How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.

Br J Haematol 2021 May 14. Epub 2021 May 14.

Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

T-cell lymphomas (TCLs) constitute a rare subset of non-Hodgkin lymphomas, with mycosis fungoides/Sézary syndrome (MF/SS) being the most common subtype of cutaneous TCLs (CTCLs). Considered an incurable but treatable disease, MF/SS management presents several challenges including diagnostic delays, debilitating effect on patients' quality of life, need for several lines of therapies, multidisciplinary care and cumulative drug toxicities limiting duration of use. The present review intends to provide an overview of the recent advances in our understanding of the biology of CTCL and how these are being leveraged to provide additional treatment options for management of advanced and recurrent disease. Read More

View Article and Full-Text PDF

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens.

Open Med (Wars) 2021 21;16(1):672-682. Epub 2021 Apr 21.

Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, 84131, Italy.

Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients' age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. Read More

View Article and Full-Text PDF

A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.

Sci Rep 2021 May 12;11(1):10069. Epub 2021 May 12.

Global Epidemiology, Janssen Research & Development, 2 Science Park Drive, Singapore, 118222, Singapore.

Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017. Treatment pathways were modelled using a Markov approach. Read More

View Article and Full-Text PDF

[Clinical features and treatment outcome of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis].

Zhonghua Xue Ye Xue Za Zhi 2021 Apr;42(4):324-331

Department of Hematology, Huadong Hospital, Fudan University, Shanghai 200040, China.

To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. We collected and analyzed the clinical data of 89 patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis who were treated at Huadong Hospital from March 2013 to May 2020. The data were analyzed via log-rank and Cox multivariate analyses. Read More

View Article and Full-Text PDF

Cardiovascular disease risks in younger versus older adult B-cell non-Hodgkin's lymphoma survivors.

Cancer Med 2021 May 12. Epub 2021 May 12.

Division of Public Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

Introduction: Young cancer survivors may be at increased risk of early-onset chronic health conditions. The aim of this population-based study is to estimate cardiovascular disease (CVD) risk among younger versus older B-cell non-Hodgkin's lymphoma (B-NHL) survivors compared with their respective general population cohorts.

Methods: B-NHL survivors diagnosed from 1997 to 2015 in the Utah Cancer Registry were matched with up to five cancer-free individuals on birth year, sex, and birth state, using the statewide Utah Population Database. Read More

View Article and Full-Text PDF

Management of primary cutaneous lymphomas during the COVID-19 pandemic.

Clin Dermatol 2021 Jan-Feb;39(1):64-75. Epub 2021 Jan 9.

2nd Department of Dermatology, Cutaneous Lymphoma Unit, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.

Primary cutaneous lymphomas are defined as a heterogenic group of T- and B-cell non-Hodgkin lymphomas that present initially in the skin. Patients with primary cutaneous lymphomas are at a higher risk for developing complications in case of infection with the novel coronavirus severe acute respiratory syndrome coronavirus 2. The coronavirus disease 2019 (COVID-19) pandemic has affected the established diagnostic approach, staging, and therapeutic guidelines in patients with primary cutaneous lymphomas. Read More

View Article and Full-Text PDF
January 2021

Extranodal NK/T-cell lymphoma, nasal type with extensive cardiopulmonary involvement.

Autops Case Rep 2021 Mar 23;11:e2021246. Epub 2021 Mar 23.

Universidade de São Paulo, Faculdade de Medicina, Departamento de Patologia. São Paulo, SP, Brasil.

Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT) is a rare type of Non-Hodgkin's lymphoma, which usually presents with extranodal involvement and affects the nasal/upper aerodigestive tract in the classical presentation. Herein, we report the case of a 31-year-old, previously healthy, male patient diagnosed with ENKTL-NT with the involvement of the lung parenchyma and heart. Unfortunately, due to the rapid disease progression, the diagnosis was performed only at the autopsy. Read More

View Article and Full-Text PDF

Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report.

Transl Androl Urol 2021 Apr;10(4):1821-1826

Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Upper tract urothelial carcinoma (UTUC) is a rare malignant disease, and while locally advanced non-metastatic UTUC can be cured by radical nephroureterectomy (RNU), this procedure leaves patients at high risk of relapse and death from cancer. Though the FDA has currently approved five agents for the systemic immunotherapy treatment of urothelial carcinoma (UC) patients, the effect of immunotherapy in patients with recurrent UTUC still lacks specific evidence. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor which has been approved for the treatment of recurrent or refractory classical Hodgkin lymphoma in China and have achieved improvement in a verity of solid tumors with manageable safety profile. Read More

View Article and Full-Text PDF

Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.

Clin Transl Immunology 2021 29;10(4):e1268. Epub 2021 Apr 29.

Hematology Service Hospital de la Santa Creu y Sant Pau Barcelona Spain.

Objectives: Adoptive cell therapy (ACT) with mature T cells modified with a chimeric antigen receptor has demonstrated improved outcome for B-cell malignancies. However, its application for others such as Hodgkin lymphoma remains a clinical challenge. CD30 antigen, expressed in Hodgkin lymphoma cells, is absent in most healthy tissues, representing an ideal target of ACT for this disease. Read More

View Article and Full-Text PDF

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.

Chin Med J (Engl) 2021 May 6. Epub 2021 May 6.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 10021, China Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 20003, China Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China Department of Medical Oncology, 307 Hospital of Chinese People's Liberation Army, Beijing 100071, China Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer, Nanjing, Jiangsu 210009, China Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China Department of Hematology, The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, China Department of Hematology, Peking University Third Hospital, Beijing 100191, China Department of Oncology, Jilin University First Affiliated Hospital, Changchun, Jilin 130021, China Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China Department of Hematology, Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China Department of Hematology, Guangdong General Hospital, Guangzhou, Guangdong 510062, China Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150001, China Department of Hematology, Chinese PLA General Hospital, Beijing 100038, China Department of Hematology, Shanghai Ruijin Hospital, Shanghai 200020, China Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China Department of Drug Metabolism and Pharmacokinetics, Teva Branded Pharmaceutical Products R&D Inc., West Chester, PA 19380, USA.

Background: Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported evaluation of the efficacy, safety, and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab treatment.

Methods: This was a prospective, multicenter, open-label, single-arm, phase 3 study (NCT01596621; C18083/3076) with a 2-year follow-up period. Read More

View Article and Full-Text PDF

Cellular Therapies for Mantle Cell Lymphoma.

Transplant Cell Ther 2021 May 6;27(5):363-370. Epub 2021 Feb 6.

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida. Electronic address:

Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible for intensive therapies are offered an autologous hematopoietic cell transplant (HCT) as front-line consolidation followed by rituximab maintenance. Allogeneic HCT is an option for younger and fit patients with high-risk disease or in patients who have relapsed after autologous HCT. Read More

View Article and Full-Text PDF

Gastrointestinal and oncologic outcomes of pediatric gastrointestinal lymphoma following upfront resection or biopsy of bowel masses.

Pediatr Surg Int 2021 May 8. Epub 2021 May 8.

Department of Paediatric Surgery, KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore, 229899, Singapore.

Purpose: Complete upfront resection of pediatric gastrointestinal lymphomas is recommended over biopsy whenever feasible, but either approach may have adverse sequelae. We sought to compare gastrointestinal and oncological outcomes of pediatric gastrointestinal lymphomas who underwent attempted upfront resection or biopsy of the presenting bowel mass.

Methods: We retrospectively reviewed charts of children with gastrointestinal lymphomas treated on LMB89 and LMB96 protocols from 2000 to 2019 who underwent upfront gastrointestinal surgery, and compared resection and biopsy groups. Read More

View Article and Full-Text PDF

Non-Hodgkin lymphoma of bone of the femur and humerus: a case report and review of the literature.

Oxf Med Case Reports 2021 Apr 28;2021(4):omab024. Epub 2021 Apr 28.

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Lymphoma of bone is a rare neoplasm composed of malignant lymphoid cells, producing a tumefactive lesion within bone. We report a 13-year-old male who presented with progressively increasing swellings at the right shoulder and right mid-thigh for one month. Radiological images revealed lytic destructive lesions associated with soft tissue masses in both sites and a pathological fracture on the right humerus. Read More

View Article and Full-Text PDF

Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.

Leuk Res 2021 Apr 30;107:106607. Epub 2021 Apr 30.

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China. Electronic address:

The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior progression-free survival (PFS) (P = 0. Read More

View Article and Full-Text PDF

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

JAMA Oncol 2021 May 6. Epub 2021 May 6.

Division of Blood & Marrow Transplantation, Stanford University, Stanford, California.

Importance: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for PCNSL, but no consensus exists on the optimal conditioning regimens.

Objective: To assess the outcomes in patients with PCNSL undergoing AHCT with the 3 most commonly used conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU), and carmustine/etoposide/cytarabine/melphalan (BEAM). Read More

View Article and Full-Text PDF

Coronary artery bypass grafting in a patient with situs inversus totalis and Hodgkin lymphoma: Three-year follow-up report and systematic literature review.

Asian J Surg 2021 May 2. Epub 2021 May 2.

Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. Electronic address:

View Article and Full-Text PDF

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.

Haematologica 2021 May 6. Epub 2021 May 6.

Nuclear Medicine at the University of Texas MD Anderson Cancer Center.

High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment of chemosensitive relapsed classical Hodgkin lymphoma (cHL), although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR cHL patients treated with HDC/ASCT at our institution between 01/01/2005-12/31/2019. HRR criteria included primary refractory disease/relapse within 1 year, extranodal extension, B symptoms, requiring > 1 salvage line, or PET+ disease at ASCT. Read More

View Article and Full-Text PDF

Semiquantitative analysis of interim F-FDG PET is superior in predicting outcome in Hodgkin lymphoma patients compared to visual analysis.

Rev Esp Med Nucl Imagen Mol 2021 May 1. Epub 2021 May 1.

Onco-Hematology Department, Instituto Português de Oncologia do Porto FG, Portugal.

Purpose: To investigate the prognostic value of interim PET (PETi) in adult HL patients, comparing visual with semiquantitative analysis.

Material And Methods: Retrospective analysis of Hodgkin's Lymphoma (HL) patients diagnosed between 2012 and 2016 in the Onco-Hematology Department of Instituto Português de Oncologia - Porto (median follow-up: 46.5 months [2,6-66,4]). Read More

View Article and Full-Text PDF

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.

Cancers (Basel) 2021 Apr 29;13(9). Epub 2021 Apr 29.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). B-cell NHLs rely on Bruton's tyrosine kinase (BTK) mediated B-cell receptor signaling for survival and disease progression. However, they are often resistant to BTK inhibitors or soon acquire resistance after drug exposure resulting in the drug-tolerant form. Read More

View Article and Full-Text PDF

Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management.

J Am Acad Dermatol 2021 May 1. Epub 2021 May 1.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with clinicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy. Staging and treatment recommendations vary depending on the subtype, clinical behavior, and treatment response. Read More

View Article and Full-Text PDF

Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome - Part I: Clinical and histologic features and diagnosis.

J Am Acad Dermatol 2021 Apr 30. Epub 2021 Apr 30.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than Mycosis Fungoides (MF) and Sézary syndrome (SS) account for approximately one-third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified. Read More

View Article and Full-Text PDF

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.

Cancer Sci 2021 May 3. Epub 2021 May 3.

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, and therefore timing of drug administration in relation to HD sessions must be carefully planned. Read More

View Article and Full-Text PDF

Lymphoma Masquerading as an Ear Mass.

Cureus 2021 Mar 29;13(3):e14180. Epub 2021 Mar 29.

Internal Medicine, University of Texas Health Science Center at Houston, Houston, USA.

Due to the infrequently reported location, malignancies of the ear are usually misdiagnosed at the time of first presentation. To the best of our knowledge, there have been no reports in literature regarding diffuse large B-cell lymphoma (DLBCL) presenting as an ear mass, as was seen in our patient. We describe a case of a 38-year-old gentleman who presented with four months of worsening dyspnea on exertion and nonproductive cough. Read More

View Article and Full-Text PDF

Binucleate Cells in Cytosmears: What do They Signify?

J Cytol 2021 Jan-Mar;38(1):38-43. Epub 2021 Feb 16.

Department of Pathology, Pondicherry Institute of Medical Sciences, Pondicherry, India.

Background: Although the classic Reed-Sternberg (RS) cell is considered a diagnostic of Hodgkin's disease, RS-like cells have been noted in various benign and malignant conditions. The presence of these cells can be a diagnostic challenge.

Aims: Our aim was to see if cells morphologically resembling or identical to RS cells occur in conditions other than Hodgkin lymphoma (HL) and what proportion of cases show binucleate cells in various benign and malignant conditions. Read More

View Article and Full-Text PDF
February 2021